Understanding mechanisms of acquired resistance to afatinib +cetuximab in EGFR-mutant lung cancer

NIAID Data Ecosystem70

Supplementary Dataset 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

XLSX file - 109K, Tumor cell line profiling of G�6976 sensitivity.

Figshare2013-02-01 更新30

Discovery of 1‑{(3 R ,4 R )‑3-[({5-Chloro-2-[(1-methyl‑1 H ‑pyrazol-4-yl)amino]‑7 H ‑pyrrolo[2,3‑ d ]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants

EGFRT790M抑制剂

靶向耐药突变药物研发

First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients’ disease progresses, often dr

NIAID Data Ecosystem20

Supplementary Dataset 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

资源简介：

相关数据集